KR20180132807A - 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제 - Google Patents

신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제 Download PDF

Info

Publication number
KR20180132807A
KR20180132807A KR1020187031919A KR20187031919A KR20180132807A KR 20180132807 A KR20180132807 A KR 20180132807A KR 1020187031919 A KR1020187031919 A KR 1020187031919A KR 20187031919 A KR20187031919 A KR 20187031919A KR 20180132807 A KR20180132807 A KR 20180132807A
Authority
KR
South Korea
Prior art keywords
tdp
seq
mitochondrial
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187031919A
Other languages
English (en)
Korean (ko)
Inventor
싱롱 왕
Original Assignee
케이스 웨스턴 리저브 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케이스 웨스턴 리저브 유니버시티 filed Critical 케이스 웨스턴 리저브 유니버시티
Publication of KR20180132807A publication Critical patent/KR20180132807A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
KR1020187031919A 2016-04-07 2017-04-07 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제 Ceased KR20180132807A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662319580P 2016-04-07 2016-04-07
US62/319,580 2016-04-07
US201662328484P 2016-04-27 2016-04-27
US62/328,484 2016-04-27
PCT/US2017/026675 WO2017177178A1 (en) 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
KR20180132807A true KR20180132807A (ko) 2018-12-12

Family

ID=60000683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187031919A Ceased KR20180132807A (ko) 2016-04-07 2017-04-07 신경퇴행성 질환의 치료용 tdp-43 미토콘드리아 국소화 억제제

Country Status (9)

Country Link
US (2) US11124553B2 (OSRAM)
EP (1) EP3440094B1 (OSRAM)
JP (1) JP2019513752A (OSRAM)
KR (1) KR20180132807A (OSRAM)
CN (1) CN109563130A (OSRAM)
AU (1) AU2017248353A1 (OSRAM)
CA (1) CA3020344A1 (OSRAM)
SG (1) SG11201808829VA (OSRAM)
WO (1) WO2017177178A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040945A (ko) 2020-09-24 2022-03-31 재단법인대구경북과학기술원 Hdac6의 tdp-43 단백질병증 예방 또는 치료제로서의 용도
WO2024181693A1 (ko) * 2023-02-28 2024-09-06 (주)케어젠 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물
KR20250016616A (ko) 2023-07-20 2025-02-04 충북대학교 산학협력단 c­Abl에 의한 TDP­43의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645557B1 (en) 2017-06-28 2024-10-23 The Cleveland Clinic Foundation Treatment of nervous system injury and neurodegenerative disorders and related conditions
CN113683703B (zh) * 2020-05-18 2023-08-15 中国人民解放军陆军军医大学第二附属医院 一种hTERT靶向物及其用途
WO2021247893A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroaromatic amide compounds and uses thereof
CN114057858B (zh) * 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のtdp−43を測定する方法及び装置
CN113450336B (zh) * 2021-07-01 2022-10-25 维柯基科技(上海)有限公司 一种多孔荧光微阵列图像的处理方法、装置、计算机设备及计算机可读存储介质
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
JP3150340B2 (ja) 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
JPH09500783A (ja) 1993-05-21 1997-01-28 ターゲッティッド ジェネティクス コーポレイション シトシンデアミナーゼ(cd)遺伝子に基づく二機能性選択融合遺伝子
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
GB9723824D0 (en) * 1997-11-11 1998-01-07 Actinova Ltd Cytostatic agents
EP1305333A4 (en) 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
US20040229837A1 (en) * 2003-05-15 2004-11-18 Yijuang Chern Treatment of neurodegenerative diseases
WO2007005948A2 (en) * 2005-07-01 2007-01-11 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of viral and bacterial infections
CA2671410C (en) 2006-12-06 2016-11-22 Thomas Jefferson University Peptide and treatment for hiv-1 infection
CA2713871C (en) 2008-02-01 2018-05-22 Washington University In St. Louis Sequences associated with tdp-43 proteinopathies and methods of using the same
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2013012811A2 (en) * 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US20150045248A1 (en) * 2012-02-28 2015-02-12 National University Corporation Tokyo University Of Agriculture And Technology Method for identifying disease associated with abundance of tdp-43 in cell
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
WO2013192298A1 (en) * 2012-06-22 2013-12-27 The Scripps Research Institute Apoptosis biomarkers
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040945A (ko) 2020-09-24 2022-03-31 재단법인대구경북과학기술원 Hdac6의 tdp-43 단백질병증 예방 또는 치료제로서의 용도
WO2024181693A1 (ko) * 2023-02-28 2024-09-06 (주)케어젠 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물
KR20250016616A (ko) 2023-07-20 2025-02-04 충북대학교 산학협력단 c­Abl에 의한 TDP­43의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법

Also Published As

Publication number Publication date
EP3440094B1 (en) 2021-02-17
EP3440094A4 (en) 2019-03-20
US11124553B2 (en) 2021-09-21
EP3440094A1 (en) 2019-02-13
AU2017248353A1 (en) 2018-10-25
WO2017177178A1 (en) 2017-10-12
US20190211070A1 (en) 2019-07-11
US12129285B2 (en) 2024-10-29
CA3020344A1 (en) 2017-10-12
JP2019513752A (ja) 2019-05-30
CN109563130A (zh) 2019-04-02
SG11201808829VA (en) 2018-11-29
US20220220173A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
US12129285B2 (en) TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
JP6203215B2 (ja) プロミニン−1ペプチド断片およびその使用
AU2010362444B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
DK2627346T3 (en) Cell permeable peptide inhibitors of the JNK signal transduction pathway for use in the treatment of uveitis
CN108431021A (zh) 具有神经元损失预防和再生效果的肽以及包含该肽的组合物
JP6046493B2 (ja) プロミニン−1の血管新生促進フラグメントおよびその使用
KR20150128731A (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
US20180327458A1 (en) Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
KR20190137786A (ko) 뇌 오스테오칼신 수용체 및 인지 장애
JP2010239971A (ja) 細胞におけるペルオキシソームカタラーゼ機能の促進
US10258672B2 (en) Compositions and methods of treating root avulsion injury
US20200230207A1 (en) Treatment of bone growth disorders
JP2004508827A (ja) カルシウム結合タンパク質
EP3651785B1 (en) Compositions and methods for treating myelin disorders
US8778884B2 (en) Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto
US20240392279A1 (en) Modified protein disulfide isomerase and uses thereof
US11136362B2 (en) Peptide modulators of specific calcineurin protein-protein interactions
JP2008530029A (ja) 神経保護剤およびそれらの使用方法
US20210290727A1 (en) MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION
JPWO2006006337A1 (ja) 神経疾患の予防又は治療薬
US20140030245A1 (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200401

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210927

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210927

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I